{"url_path":"/sec/tngx/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-221677-index.html","accession_number":"0001193125-26-221677","cik":"0001819133","ticker":"TNGX","issuer_name":"Tango Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-221677-index.html","primary_entity_key":"0001819133","primary_entity_name":"Tango Therapeutics, Inc."},"word_count":100,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n \n\n(d) Exhibits\n\n \n\nExhibit No. Description\n\n99.1\n\n[Press Release issued by Tango Therapeutics, Inc. on May 13, 2026 relating to its results of operations and financial condition for the quarter ended March 31, 2026.](tngx-ex99_1.htm)\n\n \n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\nSignature\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nTANGO THERAPEUTICS, INC.\n\n \n\nDated: May 13, 2026 By: /s/ Matthew Gall\n\nName: Matthew Gall\n\nTitle: Chief Financial Officer"}